Abstract
A child with acute myelomonocytic leukemia, bone marrow eosinophilia and inv(16) received first-line therapy including etoposide (VP-16). Cytopenia and monocytosis appeared 7 months after complete remission while the child was treated with maintenance chemotherapy. Blood abnormalities persisted after discontinuation of treatment. Nine months after complete remission, t(11;11)(q13;q23) and HRX rearrangement were detected. Five months later, overt leukemia of monocytic type occurred. The responsibility of VP-16 therapy in this treatment-related acute myelocytic leukemia is discussed.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Blotting, Southern
-
Chromosomes, Human, Pair 11*
-
DNA-Binding Proteins / genetics*
-
Etoposide / adverse effects*
-
Female
-
Gene Rearrangement*
-
Histone-Lysine N-Methyltransferase
-
Humans
-
In Situ Hybridization, Fluorescence
-
Karyotyping
-
Leukemia, Monocytic, Acute / chemically induced
-
Leukemia, Monocytic, Acute / genetics*
-
Leukemia, Myelomonocytic, Acute / drug therapy*
-
Myeloid-Lymphoid Leukemia Protein
-
Neoplasms, Second Primary / chemically induced
-
Neoplasms, Second Primary / genetics*
-
Proto-Oncogenes*
-
Transcription Factors*
-
Translocation, Genetic*
Substances
-
DNA-Binding Proteins
-
KMT2A protein, human
-
Transcription Factors
-
Myeloid-Lymphoid Leukemia Protein
-
Etoposide
-
Histone-Lysine N-Methyltransferase